Prostate Cancer Equipment & Supplies
178 equipment items found
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® cabazitaxel is an enhanced version of leading prostate cancer drug cabazitaxel (Jevtana®). Cabazitaxel (Jevtana®) had global sales of €536M in 2020 despite having multiple US FDA “Black Box” warnings. ...
by:Pars Isotope Co based inTehran, IRAN
The PARS-LUTOPSMA kit is an innovative theranostic radiopharmaceutical developed by Parsisotope Company, designed specifically for the treatment of metastatic prostate cancer. This kit is notable for being the first of its kind globally, and is used in conjunction with the Lu-177 radioisotope. It targets prostate-specific membrane antigen (PSMA), ...
by:Pars Isotope Co based inTehran, IRAN
Lu-177-PSMA is a theranostic radiopharmaceutical designed for the treatment of metastatic prostate cancer. Employing the Peptide Receptor Radionuclide Therapy (PRRT) technique, it selectively targets and binds to prostate tumor cells, facilitating the destruction of malignant cells. This unique action stems from its characteristic as a gamma ...
Manufactured by:Nanostics Inc. based inEdmonton, ALBERTA (CANADA)
Our lead product, ClarityDx Prostate® is designed to be a highly accurate test to assist in diagnosing clinically significant prostate cancer and improve prostate healthcare decisions. Validation of ClarityDX Prostate® is ongoing in a 2800 patient clinical study designed to meet regulatory ...
Manufactured by:Ferring Pharmaceuticals based inSaint-Prex, SWITZERLAND
FIRMAGON® (degarelix) is a treatment for men with advanced hormone-dependent prostate cancer. It has a novel mechanism of action that is different from traditional LHRH agonist therapy commonly used. Decreasing testosterone levels can cause the cancer cells to die, thus reducing the size of the tumour and delaying its growth. ...
Manufactured by:EDAP TMS based inVaulx-en-Velin, FRANCE
Focal treatment strategy for Prostate Cancer (PCa) is playing a growing role in today's surgical practice. By combining the latest imaging and treatment technologies, Focal One® brings the answer to current requirements for ideal focal therapy: accurate and MR-fused imaging, non-invasive approach, precise and efficient therapeutic HIFU energy and treatment ...
Manufactured by:Cancer Targeted Technology based inWoodinville, WASHINGTON (USA)
CTT1057 is an innovative 18F-labeled PET agent for prostate cancer that can be imaged within 2 hours of administration. CTT1057 will specifically and sensitively detect cancer that has escaped from the prostate as well as distant metastatic disease including bone metastases with greater precision and resolution than current ...
Manufactured by:MDxHealth based inIrvine, CALIFORNIA (USA)
SelectMDx Helps Physicians Determine if a Patient is at Higher or Lower Risk for Prostate Cancer and Which Men Can Safely Avoid Biopsy. A non-invasive urine test (“liquid biopsy”), SelectMDx measures the expression of two mRNA cancer-related biomarkers (HOXC6 and DLX1).1 The test provides binary results that, when combined with the ...
Manufactured by:MDxHealth based inIrvine, CALIFORNIA (USA)
ConfirmMDx Addresses Prostate Biopsy Sampling Error and the False-Negative Biopsy Dilemma. “Rule-in” high-risk men who have had a previous negative biopsy result, may be harboring undetected cancer (a false-negative biopsy result), and therefore may benefit from a repeat biopsy and appropriate treatment. “Rule-out” otherwise ...
Manufactured by:OncoDiag based inMiserey, FRANCE
An accurate tissue-based test to predict non-evolutive localized prostate cancer (LPCa). ...
Manufactured by:Cancer Targeted Technology based inWoodinville, WASHINGTON (USA)
CTT’s lead therapeutic product, CTT1403, is a PSMA-targeted 177Lu-labeled agent for prostate cancer that can has superior binding characteristics, long circulation half-life, enhanced tumor uptake and unparalleled anti-tumor efficacy. CTT1403 will specifically deliver the radionuclide, 177Lu, minimizing toxic side effects and more effectively treating ...
Manufactured by:Vitro Biopharma based inGolden, COLORADO (USA)
High passage capabilities. Expands in VitroPlusIII Low Serum, Complete Medium (Vitro Biopharma, Cat. No. PC00B1–optimized for high growth rates, reduced doubling times, healthy cells, and stability). Able to grow in low oxygen (1% - 5% O2). Available for research ...
Manufactured by:UroTech based inFranklin, TENNESSEE (USA)
Cryoablation is emerging as an effective, minimally invasive treatment for localized prostate cancer. Cryoablation is revolutionizing localized prostate cancer treatment by abolishing the "one shot" treatment method of having only one chance at treating the cancer. When used as a primary method of treatment, ...
by:Antech Diagnostics based inFountain Valley, CALIFORNIA (USA)
Antech’s molecular diagnostics use and develop novel technologies that enable faster and more personalized diagnoses. With tests such as CADET® BRAF/PLUS and comprehensive PCR panels, we are the innovative leader in molecular research and testing. ...
Manufactured by:OTraces Inc. based inSykesville, MARYLAND (USA)
TME Liquid Biopsy Dx immunoassay test for assessing progression of low Gleason Score prostate cancer to high Gleason Score aggressive prostate cancer, Active ...
Manufactured by:Isotopia Molecular Imaging based inPetah Tikva, ISRAEL
Prostate cancer is one of the leading causes of morbidity and mortality in men in the western world, and the second most common cancer in men worldwide. Imaging of the prostate-specific membrane antigen (PSMA) has become an essential tool for managing patients with recurrent prostate cancer and ...
Manufactured by:OPKO Health, Inc. based inMiami, FLORIDA (USA)
The 4Kscore® Test is used by health care professionals to improve the accuracy of prostate cancer diagnosis after an abnormal prostate-specific antigen (PSA) test result, or digital rectal exam, before the decision is made to biopsy. The 4Kscore® Test provides a risk score (4KScore) for finding aggressive prostate ...
Manufactured by:Isotopia Molecular Imaging based inPetah Tikva, ISRAEL
A Prostate-Specific Membrane Antigen (PSMA) imaging agent for the detection & staging of prostate ...
Manufactured by:LAVA Therapeutics N.V. based inUtrecht, NETHERLANDS
LAVA-1207, a gamma-delta bsTCE targeting the prostate specific membrane antigen (PSMA), has also demonstrated preclinical proof-of-concept. We expect to initiate a Phase I/IIa trial in metastatic castration-resistant prostate cancer in the second half of ...
Manufactured by:Vivesto AB based inSolna, SWEDEN
Docetaxel micellar is a product candidate in early clinical development and is a novel formulation that combines XR-17 with docetaxel - a well-established cytotoxin, currently administered intravenously and containing ethanol. In June 2020, Vivesto partnered with the Swiss Group for Clinical Cancer Research (SAKK) with the aim of conducting the first clinical study on the ...